Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose ATG and PTCy for GVHD Prophylaxis in Haplo-HSCT
NCT03395860Phase 2Unknown
- Sponsor
- Shanghai General Hospital
- Start
- May 2017
- Primary completion
- May 2020
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of antithymocyte globulin, cyclophosphamide in graft-versus-host disease (GVHD), sponsored by Shanghai General Hospital. Status: unknown.
02
Drugs
antithymocyte globulincyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03395860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03395860.